



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: **CKI-7 2HCl**
CAS 号: **1177141-67-1**
产品货号: **Y21434**

生物活性:

Description	CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases[1][2][3][4].				
IC50 & Target	CK1 6 μM (IC50)	CK1 8.5 μM (Ki)	Cdc7	SGK	MSK1
In Vitro	CKI-7 (0.1-10 μM; 5 days; ES cells) treatment significantly increases the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner[1].				
	CKI-7 (5 μM; 5 days; ES cells) treatment suppresses SFEB-induced β-catenin stabilization on day 5, indicating that CKI-7 inhibits Wnt signaling[1].				
	RT-PCR[1]				
	Cell Line:		Mouse ES cells		
	Concentration:		0.1-10 μM		
	Incubation Time:		5 days		
	Result:		Significantly increased the expression of the early neuroectodermal marker Sox1 and the number of cells positive for the neural markers nestin and βIII-tubulin, in a concentration-dependent manner.		
	Western Blot Analysis[1]				
	Cell Line:		Mouse ES cells		
	Concentration:		5 μM		
Incubation Time:		5 days			
Result:		Suppressed SFEB-induced 尾-catenin stabilization on day 5.			
In Vivo	In vivo dose-dependent anti-tumor activity of CKI-7 is demonstrated in a SCID-Beige mouse systemic tumor model utilizing a recently isolated Philadelphia chromosome positive acute lymphoblastic leukemia cell line. Standard cell cycle synchronization studies established that exposure to CKI-7 results in cell cycle dependent caspase 3 activation and apoptotic cell death[2].				
Solvent&Solubility	细胞实验:				
	H2O 中的溶解度 : 10 mg/mL (27.88 mM; 超声助溶 (<60° C))				
	DMSO 中的溶解度 : 5 mg/mL (13.94 mM; 超声助溶 (<60° C); 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO)				
	Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
		1 mM	2.7881 mL	13.9404 mL	27.8808 mL
5 mM		0.5576 mL	2.7881 mL	5.5762 mL	
10 mM		0.2788 mL	1.3940 mL	2.7881 mL	
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。					



	储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。
参考文献	[1]. Osakada F, et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. J Cell Sci. 2009 Sep 1;122(Pt 17):3169-79. [2]. Mark G. Frattini, et al. Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo. Blood (2008) 112 (11): 2668. [3]. Chijiwa T, et al. A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis. J Biol Chem. 1989 Mar 25;264(9):4924-7. [4]. Rena G, et al. D4476, a cell-permeant inhibitor of CK1, suppresses the site-specific phosphorylation and nuclear exclusion of FOXO1a. EMBO Rep. 2004 Jan;5(1):60-5.

完整储备液配制表:

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。

储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。

可选溶剂	质量 溶剂体积 浓度	1 mg	5 mg	10 mg	25 mg
DMSO / H ₂ O	1 mM	2.7881 mL	13.9404 mL	27.8808 mL	69.7020 mL
	5 mM	0.5576 mL	2.7881 mL	5.5762 mL	13.9404 mL
	10 mM	0.2788 mL	1.3940 mL	2.7881 mL	6.9702 mL
H ₂ O	15 mM	0.1859 mL	0.9294 mL	1.8587 mL	4.6468 mL
	20 mM	0.1394 mL	0.6970 mL	1.3940 mL	3.4851 mL
	25 mM	0.1115 mL	0.5576 mL	1.1152 mL	2.7881 mL

备注: 如您选择水作为储备液, 请稀释至工作液后, 再用 0.22 μm 的滤膜过滤除菌后使用。